ABCB1、SLCO1B1和UGT1A1基因多态性与一线伊立替康治疗的转移性结直肠癌患者的毒性相关。
ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
作者信息
Rhodes Katrin E, Zhang Wu, Yang Dongyun, Press Oliver A, Gordon Michael, Vallböhmer Daniel, Schultheis Anne M, Lurje Georg, Ladner Robert D, Fazzone William, Iqbal Syma, Lenz Heinz-Josef
机构信息
Divison of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.
出版信息
Drug Metab Lett. 2007 Jan;1(1):23-30. doi: 10.2174/187231207779814328.
We tested specific gene polymorphisms known to be involved in the irinotecan (CPT-11) metabolic pathway. The combination of at least one SLCO1B1 521 T allele, one ABCB1 1236 C allele and one UGT1A1*28 variant 7 repeat demonstrated a statistically significant association with Grade 3/4 toxicities in metastatic colorectal cancer patients.
我们检测了已知参与伊立替康（CPT - 11）代谢途径的特定基因多态性。至少一个SLCO1B1 521 T等位基因、一个ABCB1 1236 C等位基因和一个UGT1A1*28变体7次重复的组合，在转移性结直肠癌患者中与3/4级毒性表现出统计学上的显著关联。
Zotero 插件